NCT03278132View on ClinicalTrials.gov

Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 16, 2017

Primary Completion Date

September 15, 2017

Study Completion Date

September 15, 2017

Conditions
Hand, Foot and Mouth Disease
Interventions
BIOLOGICAL

EV71 vaccine

Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.

Trial Locations (1)

312300

Shangyu District Center for Disease Control and Prevention, Shaoxing

All Listed Sponsors
collaborator

Zhejiang Provincial Center for Disease Control and Prevention

OTHER_GOV

collaborator

Shangyu District Center for Disease Control and Prevention

UNKNOWN

lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT03278132 - Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine | Biotech Hunter | Biotech Hunter